Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Am J Respir Cell Mol Biol ; 69(3): 321-327, 2023 09.
Article in English | MEDLINE | ID: mdl-36848314

ABSTRACT

Beyond the acute infection of coronavirus disease (COVID-19), concern has arisen about long-term effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The aim of our study was to analyze if there is any biomarker of fibrogenesis in patients with COVID-19 pneumonia capable of predicting post-COVID-19 pulmonary sequelae. We conducted a multicenter, prospective, observational cohort study of patients admitted to a hospital with bilateral COVID-19 pneumonia. We classified patients into two groups according to severity, and blood sampling to measure matrix metalloproteinase 1 (MMP-1), MMP-7, periostin, and VEGF and respiratory function tests and high-resolution computed tomography were performed at 2 and 12 months after hospital discharge. A total of 135 patients were evaluated at 12 months. Their median age was 61 (interquartile range, 19) years, and 58.5% were men. We found between-group differences in age, radiological involvement, length of hospital stay, and inflammatory laboratory parameters. Differences were found between 2 and 12 months in all functional tests, including improvements in predicted forced vital capacity (98.0% vs. 103.9%; P = 0.001) and DlCO <80% (60.9% vs. 39.7%; P = 0.001). At 12 months, 63% of patients had complete high-resolution computed tomography resolution, but fibrotic changes persisted in 29.4%. Biomarker analysis demonstrated differences at 2 months in periostin (0.8893 vs. 1.437 ng/ml; P < 0.001) and MMP-7 (8.7249 vs. 15.2181 ng/ml; P < 0.001). No differences were found at 12 months. In multivariable analysis, only 2-month periostin was associated with 12-month fibrotic changes (odds ratio, 1.0013; 95% confidence interval, 1.0006-1.00231; P = 0.003) and 12-month DlCO impairment (odds ratio, 1.0006; 95% confidence interval, 1.0000-1.0013; P = 0.047). Our data suggest that early periostin postdischarge could predict the presence of fibrotic pulmonary changes.


Subject(s)
COVID-19 , SARS-CoV-2 , Male , Humans , Middle Aged , Female , Prospective Studies , Matrix Metalloproteinase 7 , Aftercare , Patient Discharge , Cohort Studies , Biomarkers , Fibrosis , Hospitals
2.
Respir Res ; 23(1): 242, 2022 Sep 12.
Article in English | MEDLINE | ID: mdl-36096801

ABSTRACT

BACKGROUND: The coronavirus disease (COVID-19) pandemic has already affected more than 400 million people, with increasing numbers of survivors. These data indicate that a myriad of people may be affected by pulmonary sequelae of the infection. The aim of this study was to evaluate pulmonary sequelae in patients with bilateral COVID-19 pneumonia according to severity 1 year after hospital discharge. METHODS: COVID-FIBROTIC is a multicenter prospective observational cohort study for admitted patients with bilateral COVID-19 pneumonia. Pulmonary functional outcomes and chest computed tomography sequelae were analyzed 12 months after hospital discharge and we classified patients into three groups according to severity. A post hoc analysis model was designed to establish how functional test changed between groups and over time. A multivariable logistic regression model was created to study prognostic factors for lung diffusion impairment and radiological fibrotic-like changes at 12 months. RESULTS: Among 488 hospitalized patients with COVID-19 pneumonia, 284 patients had completed the entire evaluation at 12 months. Median age was 60.5 ± 11.9 and 55.3% were men. We found between-group differences in male sex, length of hospital stay, radiological involvement and inflammatory laboratory parameters. The functional evaluation of pulmonary sequelae showed that severe patients had statistically worse levels of lung diffusion at 2 months but no between group differences were found in subsequent controls. At 12-month follow up, however, we found impaired lung diffusion in 39.8% unrelated to severity. Radiological fibrotic-like changes at 12 months were reported in 22.7% of patients (102/448), only associated with radiological involvement at admission (OR: 1.55, 95% CI 1.06-2.38; p = 0.02) and LDH (OR: 0.99, 95% CI 0.98-0.99; p = 0.046). CONCLUSION: Our data suggest that a significant percentage of individuals would develop pulmonary sequelae after COVID 19 pneumonia, regardless of severity of the acute process. Trial registration clinicaltrials.gov NCT04409275 (June 1, 2020).


Subject(s)
COVID-19 , Pneumonia , Aged , COVID-19/diagnostic imaging , Female , Follow-Up Studies , Humans , Lung/diagnostic imaging , Male , Middle Aged , Pneumonia/complications , Prospective Studies
3.
Ann N Y Acad Sci ; 1290: 37-51, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23855464

ABSTRACT

Primary prevention of cardiovascular disease (CVD) aims to avoid a first event in subjects that are at risk but have not yet been diagnosed with heart disease. Secondary prevention of CVD aims to avoid new events in patients with established heart disease. Both approaches involve clinical intervention and implementation of healthy lifestyles. The grape and wine polyphenol resveratrol (3,5,4'-trihydroxy-trans-stilbene) has shown cardioprotective benefits in humans. Most of these approaches deal with rather high doses and short follow-ups, and do not address the issue of long-term resveratrol consumption safety, especially in medicated individuals. Here, we review the trials conducted with resveratrol in patients at risk for or with established CVD, focusing on the two longest human clinical trials reported so far (1-year follow-up). We also discuss the expectations for resveratrol from a dietary and clinical perspective in relation to CVD. However, statistically significant changes in CVD-risk markers do not necessarily equal clinical significance in the daily care of patients.


Subject(s)
Cardiovascular Diseases/diet therapy , Cardiovascular Diseases/prevention & control , Primary Prevention/methods , Secondary Prevention/methods , Stilbenes/administration & dosage , Animals , Cardiotonic Agents/administration & dosage , Cardiotonic Agents/metabolism , Cardiovascular Diseases/metabolism , Clinical Trials as Topic/methods , Humans , Resveratrol , Vitis/metabolism , Wine
4.
Pharmacol Res ; 72: 69-82, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23557933

ABSTRACT

Numerous studies have shown that resveratrol (RES) exerts anti-inflammatory effects but human trials evidencing these effects in vivo are limited. Furthermore, the molecular mechanisms triggered in humans following the oral intake of RES are not yet understood. Therefore, the purpose of this study was to investigate the molecular changes in peripheral blood mononuclear cells (PBMCs) associated to the one-year daily intake of a RES enriched (8 mg) grape extract (GE-RES) in hypertensive male patients with type 2 diabetes mellitus (T2DM). We used microarrays and RT-PCR to analyze expression changes in genes and microRNAs (miRs) involved in the inflammatory response modulated by the consumption of GE-RES in comparison to a placebo and GE lacking RES. We also examined the changes in several serobiochemical variables, inflammatory and fibrinolytic markers. Our results showed that supplementation with GE or GE-RES did not affect body weight, blood pressure, glucose, HbA1c or lipids, beyond the values regulated by gold standard medication in these patients. We did not find either any significant change on serum inflammatory markers except for a significant reduction of ALP and IL-6 levels. The expression of the pro-inflammatory cytokines CCL3, IL-1ß and TNF-α was significantly reduced and that of the transcriptional repressor LRRFIP-1 increased in PBMCs from patients taking the GE-RES extract. Also, a group of miRs involved in the regulation of the inflammatory response: miR-21, miR-181b, miR-663, miR-30c2, miR-155 and miR-34a were found to be highly correlated and altered in the group consuming the GE-RES for 12 months. Our results provide preliminary evidence that long-term supplementation with a grape extract containing RES downregulates the expression of key pro-inflammatory cytokines with the involvement of inflammation-related miRs in circulating immune cells of T2DM hypertensive medicated patients and support a beneficial immunomodulatory effect in these patients.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Coronary Artery Disease/diet therapy , Cytokines/genetics , Diabetes Mellitus, Type 2/diet therapy , Hypertension/diet therapy , Leukocytes, Mononuclear/drug effects , MicroRNAs/genetics , Stilbenes/therapeutic use , Aged , Coronary Artery Disease/complications , Coronary Artery Disease/genetics , Coronary Artery Disease/immunology , Cytokines/immunology , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/immunology , Dietary Supplements/analysis , Gene Expression Regulation/drug effects , Humans , Hypertension/complications , Hypertension/genetics , Hypertension/immunology , Inflammation/drug therapy , Inflammation/genetics , Inflammation/immunology , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Male , Middle Aged , Models, Molecular , Plant Extracts/therapeutic use , Resveratrol , Transcriptome/drug effects , Vitis/chemistry
5.
Cardiovasc Drugs Ther ; 27(1): 37-48, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23224687

ABSTRACT

PURPOSE: The grape and wine polyphenol resveratrol exerts cardiovascular benefits but evidence from randomized human clinical trials is very limited. We investigated dose-depending effects of a resveratrol-containing grape supplement on stable patients with coronary artery disease (CAD) treated according to currently accepted guidelines for secondary prevention of cardiovascular disease. METHODS: In a triple-blind, randomized, placebo-controlled, one-year follow-up, 3-arm pilot clinical trial, 75 stable-CAD patients received 350 mg/day of placebo, resveratrol-containing grape extract (grape phenolics plus 8 mg resveratrol) or conventional grape extract lacking resveratrol during 6 months, and a double dose for the following 6 months. Changes in circulating inflammatory and fibrinolytic biomarkers were analyzed. Moreover, the transcriptional profiling of inflammatory genes in peripheral blood mononuclear cells (PBMCs) was explored using microarrays and functional gene expression analysis. RESULTS: After 1 year, in contrast to the placebo and conventional grape extract groups, the resveratrol-containing grape extract group showed an increase of the anti-inflammatory serum adiponectin (9.6 %, p = 0.01) and a decrease of the thrombogenic plasminogen activator inhibitor type 1 (PAI-1) (-18.6 %, p = 0.05). In addition, 6 key inflammation-related transcription factors were predicted to be significantly activated or inhibited, with 27 extracellular-space acting genes involved in inflammation, cell migration and T-cell interaction signals presenting downregulation (p < 0.05) in PBMCs. No adverse effects were detected in relation to the study products. CONCLUSIONS: Chronic daily consumption of a resveratrol-containing grape nutraceutical could exert cardiovascular benefits in stable-CAD patients treated according to current evidence-based standards, by increasing serum adiponectin, preventing PAI-1 increase and inhibiting atherothrombotic signals in PBMCs.


Subject(s)
Adiponectin/blood , Anti-Inflammatory Agents/therapeutic use , Coronary Artery Disease/drug therapy , Leukocytes, Mononuclear/drug effects , Stilbenes/therapeutic use , Transcription Factors/genetics , Vitis/chemistry , Anti-Inflammatory Agents/administration & dosage , Coronary Artery Disease/blood , Coronary Artery Disease/genetics , Coronary Artery Disease/immunology , Dietary Supplements , Down-Regulation , Female , Humans , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Male , Middle Aged , Plant Extracts/administration & dosage , Plant Extracts/therapeutic use , Research Design , Resveratrol , Stilbenes/administration & dosage , Treatment Outcome
6.
Mol Nutr Food Res ; 56(5): 810-21, 2012 May.
Article in English | MEDLINE | ID: mdl-22648627

ABSTRACT

SCOPE: The cardioprotective role of resveratrol as part of the human diet is not yet clear. Our aim was to investigate the effect of a grape supplement containing 8 mg resveratrol in oxidized LDL (LDLox), apolipoprotein-B (ApoB), and serum lipids on statin-treated patients in primary cardiovascular disease prevention (PCP). METHODS AND RESULTS: A triple-blind, randomized, placebo-controlled trial was conducted. Seventy-five patients (three parallel arms) consumed one capsule (350 mg) daily for 6 months containing resveratrol-enriched grape extract (GE-RES, Stilvid®), grape extract (GE, similar polyphenolic content but no resveratrol), or placebo (maltodextrin). After 6 months, no changes were observed in the placebo group and only LDL cholesterol (LDLc) decreased by 2.9% (p = 0.013) in the GE group. In contrast, LDLc (-4.5%, p = 0.04), ApoB (-9.8%, p = 0.014), LDLox (-20%, p = 0.001), and LDLox/ApoB (-12.5%, p = 0.000) decreased in the Stilvid® group, whereas the ratio non-HDLc (total atherogenic cholesterol load)/ApoB increased (8.5%, p = 0.046). No changes were observed in hepatic, thyroid, and renal function. No adverse effects were observed in any of the patients. CONCLUSION: This GE-RES reduced atherogenic markers and might exert additional cardioprotection beyond the gold-standard medication in patients from PCP. The presence of resveratrol in the GE was necessary to achieve these effects.


Subject(s)
Apolipoproteins B/blood , Cardiovascular Diseases/prevention & control , Dietary Supplements , Lipoproteins, LDL/blood , Stilbenes/pharmacology , Aged , Female , Follow-Up Studies , Humans , Kidney/drug effects , Kidney/physiology , Lipids/blood , Liver/drug effects , Liver/physiology , Male , Middle Aged , Plant Extracts/pharmacology , Resveratrol , Thyroid Function Tests , Vitis/chemistry
7.
Am J Cardiol ; 110(3): 356-63, 2012 Aug 01.
Article in English | MEDLINE | ID: mdl-22520621

ABSTRACT

The search for complementary treatments in primary prevention of cardiovascular disease (CVD) is a high-priority challenge. Grape and wine polyphenol resveratrol confers CV benefits, in part by exerting anti-inflammatory effects. However, the evidence in human long-term clinical trials has yet to be established. We aimed to investigate the effects of a dietary resveratrol-rich grape supplement on the inflammatory and fibrinolytic status of subjects at high risk of CVD and treated according to current guidelines for primary prevention of CVD. Seventy-five patients undergoing primary prevention of CVD participated in this triple-blinded, randomized, parallel, dose-response, placebo-controlled, 1-year follow-up trial. Patients, allocated in 3 groups, consumed placebo (maltodextrin), a resveratrol-rich grape supplement (resveratrol 8 mg), or a conventional grape supplement lacking resveratrol, for the first 6 months and a double dose for the next 6 months. In contrast to placebo and conventional grape supplement, the resveratrol-rich grape supplement significantly decreased high-sensitivity C-reactive protein (-26%, p = 0.03), tumor necrosis factor-α (-19.8%, p = 0.01), plasminogen activator inhibitor type 1 (-16.8%, p = 0.03), and interleukin-6/interleukin-10 ratio (-24%, p = 0.04) and increased anti-inflammatory interleukin-10 (19.8%, p = 0.00). Adiponectin (6.5%, p = 0.07) and soluble intercellular adhesion molecule-1 (-5.7%, p = 0.06) tended to increase and decrease, respectively. No adverse effects were observed in any patient. In conclusion, 1-year consumption of a resveratrol-rich grape supplement improved the inflammatory and fibrinolytic status in patients who were on statins for primary prevention of CVD and at high CVD risk (i.e., with diabetes or hypercholesterolemia plus ≥1 other CV risk factor). Our results show for the first time that a dietary intervention with grape resveratrol could complement the gold standard therapy in the primary prevention of CVD.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cardiovascular Diseases/prevention & control , Dietary Supplements , Fibrinolysis/drug effects , Fruit , Inflammation/drug therapy , Phytotherapy , Plant Extracts/therapeutic use , Stilbenes/administration & dosage , Vitis , Double-Blind Method , Female , Humans , Male , Middle Aged , Resveratrol , Time Factors
8.
Europace ; 10(2): 161-3, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18208939

ABSTRACT

Pacemaker manufacturers have developed new algorithms to preserve intrinsic conduction in order to reduce unnecessary stimulation and looking for physiological pacing. This case report highlights some of the new challenges related to these algorithms which include possible ECG misinterpretations and inaccurate programming leading to potential negative consequences.


Subject(s)
Atrioventricular Block/diagnosis , Atrioventricular Block/therapy , Cardiac Pacing, Artificial , Pacemaker, Artificial/adverse effects , Aged , Algorithms , Atrioventricular Block/physiopathology , Cardiac Pacing, Artificial/adverse effects , Electrocardiography , Equipment Failure , False Positive Reactions , Female , Heart Conduction System/physiopathology , Humans
9.
Rev Esp Cardiol ; 60(12): 1233-41, 2007 Dec.
Article in Spanish | MEDLINE | ID: mdl-18082088

ABSTRACT

INTRODUCTION AND OBJECTIVES: Tumor necrosis factor-alpha (TNFalpha in patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study was to determine the prognostic value of TNFalpha in this clinical setting at six-month follow-up. METHODS: The levels of TNFalpha, C-reactive protein (CRP), interleukin 6 and type 1 soluble intercellular adhesion molecules measured within the first 10 h of symptom onset and at 48 h in 74 consecutive patients admitted with STEMI. The relationships between these levels and the incidence of ischemic events (i.e., angina, reinfarction, and death), heart failure (HF), or both (i.e., all cardiovascular events) were studied. RESULTS: Overall, TNFalpha levels were significantly higher in patients who had an ischemic event or HF than in those who did not (P<.02 for both). At 48 h, the adjusted odds ratios of those in the highest TNFalpha quartile (2.92 pg/mL) for the development of ischemic events, HF, and all cardiovascular events combined were 13.1, 9.59 and 9.75, respectively. A TNFalpha level of 2.04 pg/mL at 48 h had a sensitivity of 78% and a specificity of 72.5% in predicting a cardiovascular event of any form. The CRP level, but not the TNFalpha level, at admission was found to be an independent predictor of the development of a cardiovascular events. CONCLUSIONS: In patients with STEMI, the plasma TNFalpha level 48 h after symptom onset and the CRP level at admission were independent predictors of cardiovascular events.


Subject(s)
Angina Pectoris/blood , Heart Failure/blood , Myocardial Infarction/blood , Tumor Necrosis Factor-alpha/blood , Adult , Aged , Aged, 80 and over , Angina Pectoris/etiology , Angina Pectoris/mortality , Biomarkers/blood , C-Reactive Protein/analysis , Epidemiologic Methods , Female , Heart Failure/etiology , Heart Failure/mortality , Humans , Interleukin-6/blood , Male , Middle Aged , Myocardial Infarction/complications , Myocardial Infarction/mortality , Prognosis , Recurrence , Time Factors , Vascular Cell Adhesion Molecule-1/blood
10.
Rev. esp. cardiol. (Ed. impr.) ; 60(12): 1233-1241, dic. 2007. ilus, tab
Article in Es | IBECS | ID: ibc-63345

ABSTRACT

Introducción y objetivos. Entre la variedad de procesos inflamatorios que implican al factor de necrosis tumoral alfa (TNFα), se encuentra la enfermedad cardiovascular. Su valor pronóstico en el infarto agudo de miocardio con elevación del segmento ST (IAMEST) es poco conocido. Este estudio trata de determinar el valor pronóstico del TNFα en este marco clínico tras 6 meses de seguimiento. Métodos. Se midieron las concentraciones de TNFα, proteína C-reactiva (PCR), interleucina 6 y moléculas solubles de adhesión celular tipo 1 en las primeras 10 h tras el inicio de los síntomas y tras 48 h en 74 pacientes con IAMEST. Se correlacionaron sus valores con la incidencia de eventos isquémicos (angina, reinfarto y muerte), insuficiencia cardiaca o ambos (eventos cardiovasculares). Resultados. Los valores de TNFα fueron significativamente mayores en pacientes con eventos isquémicos o insuficiencia cardiaca que en aquellos sin eventos (p < 0,02 para todos). A las 48 h, las odds ratio (OR) ajustadas para el último cuartil de TNFα (2,92 pg/ml) eran OR = 13,1; OR = 9,59 y OR = 9,75 para el desarrollo de eventos isquémicos, insuficiencia cardiaca y eventos cardiovasculares combinados, respectivamente. La concentración de TNFα a las 48 h de 2,04 pg/ml tuvo una sensibilidad del 78% y una especificidad del 72,5% en la predicción conjunta de dichos eventos. Al ingreso, la PCR, pero no el TNFα, mostró valor predictivo independiente en el desarrollo de eventos cardiovasculares. Conclusiones. En pacientes con IAMEST, la concentración plasmática de TNFα a las 48 h y la PCR al ingreso son predictores independientes de eventos cardiovasculares (AU)


Introduction and objectives. Tumor necrosis factor-alpha (TNF-alpha) is implicated in a variety of inflammatory processes, including cardiovascular disease. Little is known about the prognostic value of TNF-alpha in patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study was to determine the prognostic value of TNF-alpha in this clinical setting at six-month follow-up. Methods. The levels of TNF-alpha, C-reactive protein (CRP), interleukin 6 and type 1 soluble intercellular adhesion molecules measured within the first 10 h of symptom onset and at 48 h in 74 consecutive patients admitted with STEMI. The relationships between these levels and the incidence of ischemic events (i.e., angina, reinfarction, and death), heart failure (HF), or both (i.e., all cardiovascular events) were studied. Results. Overall, TNF-alpha levels were significantly higher in patients who had an ischemic event or HF than in those who did not (P<.02 for both). At 48 h, the adjusted odds ratios of those in the highest TNF-alpha quartile (2.92 pg/mL) for the development of ischemic events, HF, and all cardiovascular events combined were 13.1, 9.59 and 9.75, respectively. A TNF-alpha level of 2.04 pg/mL at 48 h had a sensitivity of 78% and a specificity of 72.5% in predicting a cardiovascular event of any form. The CRP level, but not the TNF-alpha level, at admission was found to be an independent predictor of the development of a cardiovascular events. Conclusions. In patients with STEMI, the plasma TNF-alpha level 48 h after symptom onset and the CRP level at admission were independent predictors of cardiovascular events (AU)


Subject(s)
Humans , Myocardial Infarction/physiopathology , Tumor Necrosis Factor-alpha , Prospective Studies , C-Reactive Protein/analysis , Interleukin-6/analysis , Intercellular Adhesion Molecule-1/analysis , Inflammation/physiopathology , Case-Control Studies
11.
Rev Esp Cardiol ; 57(11): 1059-65, 2004 Nov.
Article in Spanish | MEDLINE | ID: mdl-15544755

ABSTRACT

INTRODUCTION AND OBJECTIVES: To analyze the profile of left atrial wall velocities by pulsed wave tissue Doppler imaging, and to compare the relationship between these observations and the transmitral and pulmonary vein flow velocities obtained by conventional pulsed Doppler echocardiography. PATIENTS AND METHOD: We studied 90 patients (50 women and 40 men, mean age 48 [22] years). Pulsed tissue Doppler images of the left atrial wall were obtained and analyzed in all subjects. The study population was then divided in two groups: group I (age < 45 years) and group II (age > 45 years). Transmitral and pulmonary vein flow velocity tracings were obtained simultaneously by pulsed Doppler echocardiography. RESULTS: With pulsed tissue Doppler interrogation of the left atrial wall, a triphasic signal was recorded in all patients, consisting of a positive wave (A1) followed by two negative waves (A2 and A3). Younger subjects (group I) showed a pattern with a prominent A2 wave and an A2/A3 ratio > 1. In older patients (group II) peak velocity of the A2 wave diminished and peak velocity of the A3 wave increased, so that the A2/A3 ratio was < 1. We found no differences in peak velocity of the A1 wave between the two age groups (13.5 (3.9) cm/s in group I vs 13.1 (5.4) cm/s in group II; P = .59). Significant concordance was observed between the transmitral flow pattern and the left atrial pulsed tissue Doppler tracing (kappa = 0.584; P < .0001). CONCLUSIONS: Evaluation of the left atrial wall using pulsed tissue Doppler imaging is feasible and reproducible. Tissue Doppler imaging provides new quantitative insights of potential use in the assessment of left atrial function.


Subject(s)
Atrial Function, Left/physiology , Heart Atria/diagnostic imaging , Adolescent , Adult , Aged , Blood Flow Velocity , Child , Echocardiography, Doppler, Pulsed , Female , Heart Atria/physiopathology , Humans , Male , Middle Aged , Pulmonary Veins/diagnostic imaging , Pulmonary Veins/physiology
12.
Rev Esp Cardiol ; 57(10): 916-23, 2004 Oct.
Article in Spanish | MEDLINE | ID: mdl-15469788

ABSTRACT

INTRODUCTION AND OBJECTIVES: C-reactive protein (CRP), whose synthesis in the liver is regulated by interleukin 6 (IL-6), is related with the prognosis for ischemic heart disease. The aim of this study was to evaluate the effect of early administration of pravastatin on plasma levels of CRP and IL-6 in patients with acute myocardial infarction and ST segment elevation. PATIENTS AND METHOD: 71 patients were randomized during the first 10 hours from the onset of symptoms to receive 40 mg of pravastatin once a day or not. CRP and IL-6 were measured on admission, 48 hours and 7 days later. CRP was also measured 2 months later. RESULTS: On admission, levels of CRP and IL-6 were similar in both groups. After 7 days of treatment the administration of pravastatin was associated with a lower level of CRP (P=.002). Mean and median CRP levels decreased from 48 hours to day 7 by 48.4% and 51.9% respectively in the pravastatin group, and by 32.5% and 15.9% respectively in the control group. In contrast, no significant differences in IL-6 levels were observed between the two groups. After 2 months of follow-up, 50% of the treated patients and 25% of the control patients had CRP levels lower than 6.6 mg/L (P=.039). CONCLUSIONS: Early administration of pravastatin in the acute phase of myocardial infarction with ST segment elevation was associated with a lower level of CRP after 7 days of treatment, with no concomitant changes in IL-6 levels.


Subject(s)
Anticholesteremic Agents/administration & dosage , C-Reactive Protein/analysis , Interleukin-6/blood , Myocardial Infarction/drug therapy , Pravastatin/administration & dosage , Aged , Data Interpretation, Statistical , Female , Humans , Male , Middle Aged , Myocardial Infarction/blood , Time Factors
13.
Rev Esp Cardiol ; 56(10): 995-1000, 2003 Oct.
Article in Spanish | MEDLINE | ID: mdl-14563294

ABSTRACT

INTRODUCTION AND OBJECTIVES: Myocardial contractile reserve studies with low-dose dobutamine echocardiography have been shown to be useful to assess functional myocardial status. However, the variables associated with contractile reserve after inotropic stimulation are not well known. PATIENTS AND METHOD: We studied 50 patients (35 men, mean age 56.4 +/- 9.5 years) with nonischemic dilated cardiomyopathy (NIDC), LVEF 28.7% +/- 8.5% and wall motion score index (WMSI) 2.42 +/- 0.34 with low-dose dobutamine echocardiography. Left ventricular contractile reserve was assessed by a differential parameter defined as the difference between rest and stress WMSI (DeltaWMSI). RESULTS: After dobutamine infusion the WMSI was 1.95 +/- 0.58; from this value we calculated a DeltaWMSI of 0.45 +/- 0.39. None of the clinical variables showed a relationship with the presence of contractile reserve. In contrast, the following echocardiographic parameters correlated with DeltaWMSI: end-diastolic (p=0.05) and end-systolic (p=0.02) diameters, end-systolic volume index (p=0.01) and LVEF (p=0.002). In the multivariate analysis, only end-diastolic diameter was an independent predictor of contractile reserve (hazard ratio=0.852; 95% CI, 0.735-0.987; p=0.03). CONCLUSIONS: Ventricular diameters, end-systolic volume index and LVEF are related with improvements in myocardial contractility after dobutamine infusion, although only end-diastolic diameter was an independent predictor of contractile reserve. Thus, this parameter should receive particular attention in evaluations of the functional status of the myocardium in patients with NIDC.


Subject(s)
Cardiomyopathy, Dilated/diagnostic imaging , Cardiomyopathy, Dilated/physiopathology , Echocardiography, Stress , Myocardial Contraction , Female , Humans , Male , Middle Aged , Predictive Value of Tests
14.
Rev Esp Cardiol ; 56(9): 873-9, 2003 Sep.
Article in Spanish | MEDLINE | ID: mdl-14519274

ABSTRACT

INTRODUCTION AND OBJECTIVES: The benefits of beta blockers in heart failure are highly dependent on dosage. This study aimed to analyze the degree of concordance between targeted (CIBIS II) and achieved doses of bisoprolol in a group of patients with stable heart failure on conventional treatment. We also evaluated functional parameters, adverse effects and the reasons for withdrawal or drop-out. PATIENTS AND METHOD: The study group consisted of 334 patients with stable systolic heart failure who were receiving conventional treatment. Treatment with bisoprolol was initiated according to current guidelines (starting dose 1.25 mg/day, with weekly increments to 5 mg/day, and then increments every four weeks to a targeted dosis of 10 mg/day). The main endpoint was the comparison between targeted dose and dose reached at each follow-up. Secondary endpoints were quality of life assessment (Minnesota Living with Heart Failure Questionnaire), functional status (New York Heart Association), ejection fraction change, and side effects during the 9-month follow-up period. RESULTS: Thirty-four (10%) patients did not finish the study: 1 because of sudden death, 2 because of surgery, and 31 because of side effects. 63% of the patients attained the maximum targeted dose; the mean dose at the end of follow-up was 8.5 mg. Functional status, quality of life and ejection fraction improved significantly between the beginning and the end of the study. Only 4 patients had severe adverse effects. CONCLUSIONS: This is the first study in Spain to show that bisoprolol can be used effectively at the maximum recommended doses, for the outpatient treatment of heart failure.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Bisoprolol/therapeutic use , Heart Failure/drug therapy , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Prospective Studies
15.
Rev. esp. cardiol. (Ed. impr.) ; 56(10): 995-1000, oct. 2003.
Article in Es | IBECS | ID: ibc-28133

ABSTRACT

Introducción y objetivos. Los estudios de reserva contráctil con dobutamina han demostrado su utilidad en la valoración del estado funcional del miocardio. Sin embargo, no se conocen bien las variables asociadas a la presencia de reserva contráctil tras la estimulación inotrópica. Pacientes y método. Con este fin, estudiamos a 50 pacientes (35 varones con una edad de 56,4 ñ 9,5 años) con miocardiopatía dilatada no isquémica (MDNI), fracción de eyección (FE) de 28,7 ñ 8,5 por ciento e índice de motilidad parietal (IMP) de 2,42 ñ 0,34, a los que se realizó una ecocardiografía de estrés con dobutamina a dosis bajas. Se evaluó la respuesta contráctil mediante un parámetro diferencial obtenido de restar del índice de motilidad parietal basal el obtenido al pico del estrés ( IMP).Resultados. Tras la dobutamina se obtuvo un IMP pico de 1,95 ñ 0,58, pudiéndose calcular un IMP medio de 0,45 ñ 0,39. Ninguna variable clínica ni electrocardiográfica mostró relación con la presencia de reserva contráctil. Por el contrario, los diámetros telediastólico (p = 0,05) y telesistólico (p = 0,02), el índice de volumen telesistólico (p = 0,01) y la FE (p = 0,002) se asociaron con la presencia de reserva contráctil. En el análisis multivariable, únicamente el diámetro telediastólico se asoció de forma independiente con el grado de reserva contráctil (OR = 0,852; IC del 95 por ciento, 0,735-0,987; p = 0,03).Conclusiones. Los diámetros ventriculares, el volumen telesistólico y la FE se relacionan con la mejoría de la contractilidad miocárdica tras la infusión de dobutamina, aunque únicamente el diámetro telediastólico es predictor independiente de la presencia de reserva contráctil. Por ello, este parámetro debe ser especialmente considerado a la hora de evaluar el estado funcional del miocardio en pacientes con MDNI (AU)


Subject(s)
Middle Aged , Male , Female , Humans , Myocardial Contraction , Echocardiography, Stress , Predictive Value of Tests , Cardiomyopathy, Dilated
16.
Rev. esp. cardiol. (Ed. impr.) ; 56(9): 873-879, sept. 2003.
Article in Es | IBECS | ID: ibc-28113

ABSTRACT

Introducción y objetivos. La eficacia clínica y pronóstica de los bloqueadores beta en la insuficiencia cardíaca depende de la dosis. Este estudio prospectivo de observación pretendió comparar las dosis de bisoprolol alcanzadas en pacientes con insuficiencia cardíaca con las recomendadas (CIBIS II). También se evaluaron los parámetros funcionales, los efectos adversos y las causas de abandono del tratamiento. Pacientes y método. Se incluyeron 334 pacientes con insuficiencia cardíaca sistólica estable con tratamiento habitual. Iniciaron tratamiento ambulatorio con bisoprolol con la dosificación progresiva recomendada (inicio con 1,25 mg/día, aumentos semanales en la misma cuantía hasta los 5 mg/día y, después, incrementos de 2,5 mg/día cada 4 semanas hasta 10 mg/día). El seguimiento máximo fue de 9 meses. La variable principal fue la comparación del promedio de la dosis tomada en cada visita con la esperada. La calidad de vida se analizó con el cuestionario Minnesotta. Resultados. Hubo 34 retiradas (10 por ciento): un paciente por fallecimiento súbito, dos por cirugía y 31 por efectos adversos. Del grupo total de pacientes, el 64 por ciento alcanzaron la dosis máxima al final del estudio; la dosis media final fue de 8,5 mg/día. El grado funcional, las puntuaciones de calidad de vida y la fracción de eyección mejoraron significativamente entre el inicio y el final del estudio. Sólo hubo cuatro reacciones adversas graves. Conclusiones. El estudio confirma la factibilidad de introducir el bisoprolol en el tratamiento ambulatorio de la insuficiencia cardíaca crónica en las dosis máximas recomendadas (AU)


Subject(s)
Middle Aged , Adult , Aged, 80 and over , Aged , Male , Female , Humans , Bisoprolol , Prospective Studies , Adrenergic beta-Antagonists , Heart Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...